Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Add To Watchlist

Recent & Breaking News (NDAQ:GILD)

Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Yescarta® in Relapsed or Refractory Indolent Non-Hodgkin Lymphomas

Business Wire September 4, 2020

Kite and HiFiBiO Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia

Business Wire September 3, 2020

Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program

Business Wire September 1, 2020

Gilead's Investigational Antiviral Veklury® (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19

Business Wire August 28, 2020

Gilead Announces Presentation of More Than 40 Abstracts From Extensive Liver Disease Programs at the Digital International Liver Congress(TM) 2020

Business Wire August 25, 2020

Some of the World's Top Companies May be Nearing a Pandemic Treatment

Livemoney August 20, 2020

Gilead Receives Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis

Business Wire August 18, 2020

Gilead Sciences and Tango Therapeutics to Expand Strategic Oncology Collaboration

Business Wire August 17, 2020

China National Medical Products Administration Approves Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)

Business Wire August 11, 2020

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury® (Remdesivir) for the Treatment of COVID-19

Business Wire August 10, 2020

These are Some of the Top Companies Nearing a Potential Pandemic Treatment

Livemoney August 5, 2020

Data Raising Hopes for a Pandemic Treatment in 2020

Livemoney August 3, 2020

Gilead Sciences Announces Third Quarter 2020 Dividend

Business Wire July 30, 2020

Gilead Sciences and Satcher Health Leadership Institute at Morehouse School of Medicine Partner to Study Racial Health Inequities Associated with COVID-19

Business Wire July 28, 2020

U.S. FDA Approves Kite's Tecartus(TM), the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma

Business Wire July 24, 2020

Gilead and Galapagos Announce Positive European CHMP Opinion for Jyseleca® (Filgotinib) for the Treatment of Adults With Moderate to Severe Rheumatoid Arthritis

Business Wire July 24, 2020

Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300 Million

Business Wire July 21, 2020

Gilead Sciences to Release Second Quarter 2020 Financial Results on Thursday, July 30, 2020

Business Wire July 16, 2020

Gilead Sciences and Arcus Biosciences Complete Closing of Their 10-Year Partnership to Co-Develop and Co-Commercialize Next-Generation Cancer Immunotherapies

Business Wire July 13, 2020

Stocks Slide as Virus Fears Grow

Livemoney July 10, 2020